Andrew X. Zhu

Aram F. Hezel

Brian M. Wolpin

Charles S. Fuchs

David P. Ryan

Eunice L. Kwak

Jackie Szymonifka

Jeffrey A. Meyerhardt

Jeffrey W. Clark

Lawrence S. Blaszkowsky

Matthew H. Kulke

Raymond C. Wadlow

Thomas A. Abrams

Abstract
               
                  Purpose.
                  Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and are approved for the treatment of patients with KRAS wild-type metastatic colorectal cancer. There are no data that describe the activity of panitumumab in patients with progressive disease on cetuximab. We performed a single-arm phase II trial of panitumumab in patients with KRAS wild-type metastatic colorectal cancer that had progressed on prior cetuximab.
               
               
                  Patients and Methods.
                  We used a two-stage study design to treat patients with panitumumab at 6 mg/kg every 14 days (cycle length = 28 days). Treatment was continued until disease progression, death, inability to tolerate panitumumab, or study withdrawal. The primary endpoint was response rate; secondary endpoints included progression-free survival and overall survival. Twenty patients were treated in the first stage, with plans to treat an additional twelve patients if there was at least one objective response. We collected blood samples at baseline and prior to cycles 2 and 3 to evaluate for the presence of anti-cetuximab and anti-panitumumab antibodies.
               
               
                  Results.
                  We treated twenty patients for a median of two cycles (range 1–4). No patients responded, and 45% had a best response of stable disease (no progression for at least two cycles). Median progression-free survival was 1.7 months and median overall survival was 5.2 months. Panitumumab was well tolerated. Thirteen patients (65%) had grade 1–2 dry skin or rash, and three patients had treatment-related grade 3 toxicities (one each with hyperglycemia, hyperbilirubinemia, and hypokalemia). No patients had detectable anti-cetuximab antibodies at any time point; one patient developed anti-panitumumab antibodies.
               
               
                  Conclusions.
                  Panitumumab has minimal benefit in patients with KRAS wild-type metastatic colorectal cancer that has progressed on prior cetuximab.
               </jats:sec

Crossref

The Oncologist

Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

Panitumumab in Patients with KRAS Wild‐Type Colorectal Cancer after Progression on Cetuximab

Panitumumab in Patients with KRAS Wild‐Type Colorectal Cancer after Progression on Cetuximab

Abstract

Similar works

Full text

Available Versions

Crossref